Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet

Inclusion Criteria: * Years 20-45 * 18 ≤ BMI \< 27kg/m² * volunteer Exclusion Criteria: * Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 28days prior to study medication dosing * Subject with symptoms of acute disease within 28days prior to study medication dosing * Subject with gastrointestinal diseases or surgery which might significantly change absorption of medicines * Use of any prescription medication within 14 days prior to study medication dosing and over-the-counter medication including oriental medication within 7 days prior to study medication dosing * Subject with known for hypersensitivity reaction to amlodipine and valsartan * Subject with any of the following conditions in laboratory test i. AST(sGOT) or ALT(sGPT) \> Upper normal limit × 1.5 ii. Total bilirubin \> Upper normal limit × 1.5 iii. eGFR\< 50mL/min ⅳ. continued serum potassium concentration abnormal status (on baseline visit, \< 3.5mEq/L or \> 5.5mEq/L) * Positive test results for HBs Ab, HCV Ab, Syphilis regain test * Drug abuse or continued excessive use of caffeine (caffeine \> five cups/day), severe heavy smoker (cigarette \> 10 cigarettes per day) and alcohol(alcohol\>30g/day) * Subject who has been taken meal which affect on the absorption, distribution, metabolism, excretion of drug, especially grapefruit juice * Clinically significant hypotension(SBP \< 100mmHg, DBP ≤65mmHg) or hypertension(SBP 100mmHg, DBP \< 65mmHg) when screening period * Participation in any clinical investigation within 60days prior to study medication dosing * Subjects with whole blood donation within 60days, component blood donation within 20days and blood transfusion within 30days prior to study medication dosing * Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator